MARAbio, a Salt Lake City, UT-based precision immunology company, raised $19M in initial Series A funding.
The round was led by MAK Capital One. As part of this new investment, Michael A. Kaufman and Craig Nemiroff of MAK will join MARAbio’s Board of Directors.
The company intends to use the funds to support commercial launch of its autism test in 2025 and development of therapeutic interventions.
MARAbio Systems is a precision immunology company with proprietary technology related to a distinct cluster of antibodies that lead to Maternal Autoantibody Related Autism (MARA). Its first product will be a test to accurately predict the likelihood of MARA in a child through a simple blood test in the mother even before clinical symptoms exist, including prior to pregnancy or as early as birth.
The company aims to detect, treat and prevent MARA, a subtype which has shown to be associated with more severe forms of autism.
FinSMEs
08/10/2024